Trastuzumab therapy in breast cancer: To reload or not to reload?

Abstract

Get full access to this article

View all access options for this article.

References

Hoffmann-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario, 6 January 2012.

Romond

Perez

Bryant

. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.

Piccart-Gebhart

Procter

Leyland-Jones

. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672.

Joensuu

Kellokumpu-Lehtinen

Bono

. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–820.

Perez

Romond

Suman

. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366–3373.

Slamon

Eiermann

Robert

. Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med 2011; 365: 1273–1283.

Harris

Ward

Dobbins

. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011; 22: 1308–1317.

Pegram

Lipton

Hayes

. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185her2/neu monoclonal antibody plus cisplatin in patients with her2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–2671.

Cobleigh

Vogel

Tripathy

. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648.

10.

Leyland-Jones

Gelmon

Ayoub

. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965–3971.

11.

Baselga

Carbonell

Castaneda-Soto

. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162–2171.

12.

Baselga

Tripathy

Mendelsohn

. Phase II study of weekly intravenous recombinant humanized anti-p185her2 monoclonal antibody in patients with her2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–744.

13.

Tokuda

Ohnishi

Shimamura

. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996; 73: 1362–1365.

14.

Pegram

Slamon

. Combination therapy with trastuzumab (HERCEPTIN®) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Sem Oncol 1999; 26(4 Suppl 12): 89–95.

15.

Felici

Di Segni

Contestabile

. Dose scheduling and pharmacokinetic (pk) study of trastuzumab in patients (pts) with her2/neu overexpressing breast cancer? J Clin Oncol 2007; 25: 1109–1109.

16.

Carter

Presta

Gorman

. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285–4289.

17.

Leyland-Jones

. Dose scheduling – Herceptin. Oncology 2001; 61(Suppl 2): 31–36.

18.

Harris

Washington

Lieberman

. A population pharmacokinetic (pk) model for trastuzumab (herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 2002; 21: abstr 488–abstr 488.